Brain and NervePub Date : 2024-12-01DOI: 10.11477/mf.1416202784
Masaki Takao
{"title":"[Franz Joseph Haydn and Subcortical Vascular Encephalopathy].","authors":"Masaki Takao","doi":"10.11477/mf.1416202784","DOIUrl":"https://doi.org/10.11477/mf.1416202784","url":null,"abstract":"<p><p>Franz Joseph Haydn was a prominent musician in the late 1700s. Researchers have speculated that Haydn may have suffered from subcortical cerebrovascular disease. These interpretations, based on biographical and other sources, might be accurate. However, given that he lived to the advanced age of 77 years, it is likely he experienced multiple pathological changes in his brain, as is commonly believed. It seems unlikely that a great man would rest in peace, because even 200 years after his death, significant interest in his chronic illnesses is still present.</p>","PeriodicalId":52507,"journal":{"name":"Brain and Nerve","volume":"76 12","pages":"1329-1333"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142787583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Brain and NervePub Date : 2024-12-01DOI: 10.11477/mf.1416202783
Masaru Mimura
{"title":"[Art Brut and Mental Aberrations].","authors":"Masaru Mimura","doi":"10.11477/mf.1416202783","DOIUrl":"https://doi.org/10.11477/mf.1416202783","url":null,"abstract":"<p><p>This review discusses the concept of the Art Brut and its origin, as proposed by Dubuffet, along with its unique development in Japan. In Japan, Art Brut has evolved in distinctive ways, particularly in psychiatry. Notably, Art Brut is not synonymous with art created by individuals with mental disorders. Instead, it refers to raw, creative art uninfluenced by existing cultural norms and conventions. Art Brut works often have a psychiatric background, but this is not a defining feature. This review highlights the work of Yuzo Saeki, a prominent Japanese artist associated with Art Brut, and draws comparisons with Jean Fautrier. Finally, this review examines the creativity and originality of individuals with mental illnesses, particularly schizophrenia, from a neuroscientific perspective. It explores genetic factors, brain function alterations, and the interaction between mental illness and creativity in the context of Art Brut. Art Brut offers a deeply moving artistic experience from a psychiatric perspective, and art therapy may play a significant role in the treatment and welfare of individuals with mental disorders. Significant aspects of this field remain unexplored, and further research and development are highly anticipated.</p>","PeriodicalId":52507,"journal":{"name":"Brain and Nerve","volume":"76 12","pages":"1319-1327"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142787578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Brain and NervePub Date : 2024-12-01DOI: 10.11477/mf.1416202781
Takayoshi Shimohata
{"title":"[Leonardo da Vinci as a Neurologist].","authors":"Takayoshi Shimohata","doi":"10.11477/mf.1416202781","DOIUrl":"https://doi.org/10.11477/mf.1416202781","url":null,"abstract":"<p><p>In addition to his versatility in painting and art, Leonardo da Vinci was extremely passionate about medicine, particularly the study of the brain. He investigated the ventricles of the brain in great detail in an attempt to locate the seat of the soul in the brain (senso comune). Pathography on Leonardo da Vinci suggests that his ability to use mirror writing and supposed attention-deficit/hyperactivity disorder may have contributed to his extraordinary creativity and tendency to be unable to complete his work. It is presumed that Leonardo da Vinci died of a stroke; however, it is speculated that ulnar or median nerve palsy led to right upper limb paralysis that prevented him from painting in his later years.</p>","PeriodicalId":52507,"journal":{"name":"Brain and Nerve","volume":"76 12","pages":"1307-1312"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142787601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Brain and NervePub Date : 2024-12-01DOI: 10.11477/mf.1416202780
Kuniyoshi L Sakai
{"title":"[The Pathography and Art of Beethoven, Revisited].","authors":"Kuniyoshi L Sakai","doi":"10.11477/mf.1416202780","DOIUrl":"https://doi.org/10.11477/mf.1416202780","url":null,"abstract":"<p><p>The musician Ludwig van Beethoven suffered from progressive hearing loss and abdominal pain, both of which can be explained by lead intoxication. With genomic analyses, Begg et al. (2023) have confirmed that the five locks of hair attributed to Beethoven were authentic. Moreover, the possible cause of his severe liver disease was revealed. Rifai et al. (2024) have observed unusually high lead levels in authenticated locks of hair from Beethoven. Based on the new pieces of evidence, we conclude that his hearing loss and gastrointestinal complaints were caused by plumbism.</p>","PeriodicalId":52507,"journal":{"name":"Brain and Nerve","volume":"76 12","pages":"1301-1306"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142787540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Brain and NervePub Date : 2024-11-01DOI: 10.11477/mf.1416202766
Yohei Iguchi, Masahisa Katsuno
{"title":"[Current Status of Drug Development for Amyotrophic Lateral Sclerosis].","authors":"Yohei Iguchi, Masahisa Katsuno","doi":"10.11477/mf.1416202766","DOIUrl":"10.11477/mf.1416202766","url":null,"abstract":"<p><p>Amyotrophic lateral sclerosis (ALS) is a progressive and fatal disease of motor neuron. Although riluzole and edaravone have been approved for the treatment of ALS, it remains a lethal disease that causes rapid motor impairment, and there is an urgent need to develop more effective treatments. Advances in understanding the pathomechanisms of ALS, efficient clinical trial design, and research support programs have led to many clinical trials for ALS both domestically and internationally.</p>","PeriodicalId":52507,"journal":{"name":"Brain and Nerve","volume":"76 11","pages":"1241-1249"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142632439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Brain and NervePub Date : 2024-11-01DOI: 10.11477/mf.1416202762
Toshio Fukutake
{"title":"[Diagnosis, Notification, and Managements of ALS: A Personal Perspective from 40 years of Experience as a Clinical Neurologist].","authors":"Toshio Fukutake","doi":"10.11477/mf.1416202762","DOIUrl":"https://doi.org/10.11477/mf.1416202762","url":null,"abstract":"<p><p>This narrative summary presents the author's 40-year experience as a clinical neurologist who treated patients with amyotrophic lateral sclerosis (ALS). Five representative cases from the author's first 20 years at Chiba University Hospital and its affiliated hospitals were selected, including a patient of respiratory-onset who was ignorantly extubated by a female relative for patient's distress to the intratracheal tube. Based on the latter 20 years of experience at the author's current hospital, the author first describes a famous patient with ALS who was being treated at this medical center before the author was assigned to this hospital and fought against ALS for 31 years before eventually succumbing to total locked-in syndrome. Thereafter, the author has summarized the ages, sex, phenotypes, comorbidities, responses to the available treatment options, and total number of years that have elapsed for the 24 patients that the author initially examined in the outpatient clinic. In terms of diagnostic delay, the author describes \"foot drop\" in patients who developed lower limb symptoms, and hoarseness in those who developed bulbar palsy. Furthermore, the author discusses issues regarding family caregiving capacity, patient's and families' understanding of notification, and medical management (i.e., medications, rehabilitation for ADL, nutrition and respiration, complications of frontotemporal dementia, and medical cooperation with other clinics and hospitals).</p>","PeriodicalId":52507,"journal":{"name":"Brain and Nerve","volume":"76 11","pages":"1205-1216"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142632440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Brain and NervePub Date : 2024-11-01DOI: 10.11477/mf.1416202768
Naoko Koide-Majima, Shinji Nishimoto, Kei Majima
{"title":"[How Can We Reconstruct Mental Imagery from Brain Activities?]","authors":"Naoko Koide-Majima, Shinji Nishimoto, Kei Majima","doi":"10.11477/mf.1416202768","DOIUrl":"10.11477/mf.1416202768","url":null,"abstract":"<p><p>Advances in machine learning and artificial intelligence (AI) have enabled the extraction of information such as perception and motor intention from neural activities, which is called neural decoding. A recent study demonstrated that mental imagery can be reconstructed from brain activity measured using functional magnetic resonance imaging. This article describes the method of mental image reconstruction and the underlying technologies that support it.</p>","PeriodicalId":52507,"journal":{"name":"Brain and Nerve","volume":"76 11","pages":"1256-1261"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142632399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Brain and NervePub Date : 2024-11-01DOI: 10.11477/mf.1416202764
Mieko Ogino
{"title":"[Palliative Care for Persons with Amyotrophic Lateral Sclerosis].","authors":"Mieko Ogino","doi":"10.11477/mf.1416202764","DOIUrl":"10.11477/mf.1416202764","url":null,"abstract":"<p><p>Palliative care in Japan is available mainly for patients with cancer, and palliative care specialists do not have sufficient experience with management of palliation in persons with amyotrophic lateral sclerosis (ALS). Treatment of ALS symptoms is an important component of palliative care, and it is important that neurologists and home care physicians familiarize themselves with palliative care for ALS in consultation with palliative care specialists. Notably, the use of opioids at the end of life differs from that of pain relief for cancer. Physicians should be mindful that opioids are not a perfect solution for palliative care of persons with ALS.</p>","PeriodicalId":52507,"journal":{"name":"Brain and Nerve","volume":"76 11","pages":"1225-1232"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142632400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Brain and NervePub Date : 2024-11-01DOI: 10.11477/mf.1416202765
Taro Ishiguro, Tetsuya Nagata, Takanori Yokota
{"title":"[Current Landscape of Tofersen in SOD-1-associated Amyotrophic Lateral Sclerosis].","authors":"Taro Ishiguro, Tetsuya Nagata, Takanori Yokota","doi":"10.11477/mf.1416202765","DOIUrl":"https://doi.org/10.11477/mf.1416202765","url":null,"abstract":"<p><p>Since the identification, in 1993, of the causative gene for familial amyotrophic lateral sclerosis (ALS), which is associated with SOD1 mutations, research has focused on the pathogenesis and therapeutics of ALS for more than 30 years. Tofersen, a highly anticipated gene-specific therapy that has been aligned with the disease-specific pathology, has been approved for marketing by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) However, as significant data on tofersen's safety and efficacy are required, the evaluation of this treatment is ongoing. This paper introduces the current clinical and commercial status of Tofersen, along with expectations for its approval in Japan.</p>","PeriodicalId":52507,"journal":{"name":"Brain and Nerve","volume":"76 11","pages":"1233-1239"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142632438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Brain and NervePub Date : 2024-11-01DOI: 10.11477/mf.1416202763
Isamu Yamakawa, Makoto Urushitani
{"title":"[Gold Coast Criteria: A New Diagnostic Paradigm in the Era of Disease-Modifying Therapy for Amyotrophic Lateral Sclerosis].","authors":"Isamu Yamakawa, Makoto Urushitani","doi":"10.11477/mf.1416202763","DOIUrl":"10.11477/mf.1416202763","url":null,"abstract":"<p><p>Significant progress has been made in the development of disease-modifying drugs for amyotrophic lateral sclerosis (ALS), with the introduction of tofersen, an antisense oligonucleotide drug for familial ALS, marking a turning point in the treatment. These drugs are most effective when administered early in the disease course, highlighting the need for improved diagnostic sensitivity. The 2020 Gold Coast Diagnostic Criteria allow ALS diagnosis in cases without upper motor neuron symptoms, potentially increasing early detection rates. However, careful differential diagnoses are necessary when applying these criteria to maintain diagnostic specificity. This review outlines the key points to consider when using the Gold Coast Criteria, balancing the need for an early diagnosis with caution to avoid overdiagnosis.</p>","PeriodicalId":52507,"journal":{"name":"Brain and Nerve","volume":"76 11","pages":"1217-1223"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142632397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
